The United States Patent and Trademark Office (USPTO) has issued patent US12582616B2, titled 'Molecular targets for modulation of dissociative and associative states,' to The Board of Trustees of the Leland Stanford Junior University. The patent, granted on March 24, 2026, details methods for treating dissociative disorders and screening agents by modulating neural activity in the posteromedial cortex.

This patent grant represents a new intellectual property right for specific therapeutic methods. While not directly imposing new compliance obligations on other entities, it signifies advancements in the field of dissociative disorder treatment and may influence future research and development strategies for pharmaceutical and biotechnology companies. Compliance officers in these sectors should be aware of this patent as it pertains to potential licensing or infringement considerations.